pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Topics in Korean Clinical Practice Guideline for Stoke (KCPGS) explaining antithrombotic therapy

1. Primary prevention of stroke
1.2. Well-documented and modifiable risk factors
1.2.4. Atrial fibrillation (2012)
1.4. Aspirin for primary stroke prevention (2011)
2. Acute stroke management
2.3. Acute treatment
2.3.2. Prevention and management of medical complication
2.3.2.1. Deep vein thrombosis prophylaxis (2009)
2.3.3. Thrombolysis
2.3.3.1. Intravenous thrombolysis (2012)
2.3.3.2. Endovascular recanalization therapy in acute ischemic stroke (2016)
2.3.4. Antiplatelet agents (2009 ➔ 2022)
2.3.5. Anticoagulants (2009 ➔ 2022)
3. Secondary prevention of stroke
3.2. Antithrombotic therapy for noncardioembolic stroke or transient ischemic attack
3.2.1. Antiplatelet therapy
3.2.1.1. Aspirin (2010)
3.2.1.2. Thienopyridine (2010)
3.2.1.3. Other antiplatelet agents: triflusal, dipyridamole, cilostazol (2012)
3.2.1.4. Antiplatelet combination therapy (2009)
3.2.2. Anticoagulants (2009)
3.2.3. Specific consideration of antiplatelet agents (2009)
3.2.3.1. Ischemic stroke while taking antiplatelet agent
3.2.3.2. Ischemic stroke mixed with hemorrhage
3.3. Antithrombotic therapy of cardioembolic stroke or transient ischemic attack
3.3.1. Anticoagulants (2009)
3.3.2. Antiplatelet therapy or combination therapy (2009)
3.3.3. Specific conditions
3.3.3.1. Atrial fibrillation (2014)
3.3.3.2. Congestive heart failure (2009)
3.3.3.3. Acute myocardial infarction (2009)
3.3.3.4. Valvular heart disease (2009)
3.4. Surgical or interventional treatment of large artery steno-occlusive disease
3.4.1. Extracranial carotid artery stenosis (2011)
3.5. Management of other specific conditions (2009)
3.5.2. Secondary prevention in ischemic stroke mixed with hemorrhage
3.5.3. Arterial dissection
3.5.4. Patent foramen ovale and atrial septal aneurysm
3.5.5. Antiphospholipid antibody syndrome
3.5.6. Venous infarction

KCPGS, Korean Clinical Practice Guideline for Stroke

Latest revision years are in parenthesis

Korean J Clin Pharm 2024;34:79-99 https://doi.org/10.24304/kjcp.2024.34.2.79
© 2024 Korean J Clin Pharm